Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kerendia is a prescription nonsteroidal mineralocorticoid receptor antagonist containing finerenone. It reduces selected kidney and cardiovascular risks in adults with chronic kidney disease associated with type 2 diabetes and selected cardiovascular risks in adults with heart failure and left ventricular ejection fraction of at least 40 percent.
read more about kerendia ...Finerenone selectively blocks mineralocorticoid receptors activated by aldosterone and cortisol. This reduces mineralocorticoid receptor-mediated sodium reabsorption and receptor overactivation in tissues including the kidneys, heart, and blood vessels.
Kerendia is used in adults with chronic kidney disease associated with type 2 diabetes or heart failure with left ventricular ejection fraction of at least 40 percent under current labeling. Safety and efficacy are not established in patients younger than 18.
The starting dose is 20 mg once daily when estimated glomerular filtration rate is at least 60 mL per minute per 1.73 square meters and 10 mg once daily when it is 25 to less than 60. Initiation is not recommended below 25. Serum potassium and kidney function guide later dose changes, with target dosing differing between the kidney disease and heart failure indications.
Kerendia can cause hyperkalemia, and risk rises as kidney function declines or baseline potassium increases. Worsening kidney function can occur in patients treated for heart failure. Strong CYP3A4 inhibitors and adrenal insufficiency are contraindications. Serum potassium and estimated glomerular filtration rate are checked before treatment and during therapy.
Kerendia is used in selected adults with chronic kidney disease associated with type 2 diabetes and in adults with heart failure with left ventricular ejection fraction of at least 40 percent.
The recommended starting dose is 20 mg once daily.
Initiation is not recommended when estimated glomerular filtration rate is below 25 mL per minute per 1.73 square meters.
Yes. Hyperkalemia is a major labeled risk and requires potassium monitoring.
Cardiovascular Events With Finerenone in Kidney Disease and Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/34449181/. Date Accessed October 7, 2026.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/33264825/. Date Accessed October 7, 2026.
Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. https://pubmed.ncbi.nlm.nih.gov/39225278/. Date Accessed October 7, 2026.
Finerenone: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a621038.html. Date Accessed October 7, 2026.
KERENDIA (Finerenone) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c. Date Accessed October 7, 2026.